FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379328087> ?p ?o ?g. }

• W4379328087 endingPage "1041" @default.
• W4379328087 startingPage "1041" @default.
• W4379328087 abstract "1041 Background: While treatment options for advanced HER2+ breast cancer have improved, HER2+ breast cancer brain metastases (BCBM) remain a clinical challenge warranting the development of additional, brain permeable HER2-targeted therapies. ZN-1041 is a brain permeable, selective HER2-targeted oral tyrosine kinase inhibitor. Preclinical studies have demonstrated efficacy and safety of ZN-1041 warranting clinical development alone and in combination with approved monoclonal antibodies or antibody drug conjugates for patients (pts) with HER2+ BCBM. Methods: Anti-tumor activity of ZN-1041 alone or in combination with trastuzumab emtansine (TDM1), trastuzumab deruxtecan (TDXd), or trastuzumab (H) plus pertuzumab (P) was evaluated in BT474 BM orthotopic xenograft models. ZN-A-1041-101-US (NCT05593094) is an on-going phase 1, multicenter, open-label study. The study comprises dose escalation of ZN-1041 monotherapy (Phase 1a) in pts with HER2+ solid tumors with or without BM, dose escalation (Phase 1b) and expansion (phase 1c) of ZN-1041 in combination with TDM1 (Arm 1), TDXd (Arm 2), or HP as maintenance therapy (Arm 3) in pts with HER2+ mBC with or without BM. The primary objectives were safety, tolerability and recommended phase 2 dose. The secondary objective includes pharmacokinetics (PK) and preliminary efficacy per RECIST 1.1. Results: Preclinically, ZN-1041 alone or combined with TDM1, TDXd or HP demonstrated significant improvement in intracranial tumor growth inhibition compared to TDM1, TDXd, or HP alone. As of data cutoff, Phase 1a (n = 7 pts) and Arm 2 of Phase 1b (n = 3 pts) were completed. Among 10 pts enrolled, 8 pts had received prior HER2 TKI. In Phase 1a, ZN-1041 was well tolerated with no dose-limiting toxicities (DLTs) or drug discontinuation due to toxicity up to a dose of 800 mg BID. Adverse reactions were mainly grade 1. The most common treatment related adverse reactions (TRAEs≥15%) were grade 1 nausea (43%) and vomiting (29%), with no ≥ grade 2 diarrhea reported. PK exposure was increased with dose escalation. In Phase 1a, one pt with mBC (without BM) achieved a confirmed partial response (PR) at 400 mg BID dose for > 15 months; one with gastric cancer achieved stable disease at the first dose level of 50mg BID for nearly 1 year. In Phase 1b, pts who had previously progressed on TDXd and/or TKI were enrolled and received ZN-1041 at a dose of 800 mg BID in combination with TDXd. Combination therapy was well tolerated with no DLTs reported. One pt with BCBM who was previously on tucatinib and TDXd had a confirmed PR. Conclusions: Safety and tolerability was observed for ZN-1041 with maximum tolerated dose 800 mg BID as monotherapy and combined with TDXd in pts with advanced HER2+ malignancies. Encouraging efficacy was observed in treatment-refractory settings. Additional safety and efficacy data of ZN-1041 in combination with TDM1, TDXd or HP are warranted. Clinical trial information: NCT05593094 ." @default.
• W4379328087 created "2023-06-05" @default.
• W4379328087 creator A5013557141 @default.
• W4379328087 creator A5021649332 @default.
• W4379328087 creator A5043744905 @default.
• W4379328087 creator A5049174232 @default.
• W4379328087 creator A5064032265 @default.
• W4379328087 creator A5066943426 @default.
• W4379328087 creator A5089865552 @default.
• W4379328087 creator A5090622915 @default.
• W4379328087 date "2023-06-01" @default.
• W4379328087 modified "2023-10-16" @default.
• W4379328087 title "Preclinical and early clinical data of ZN-1041 in combination with trastuzumab deruxtecan to treat breast cancer with or without CNS metastases." @default.
• W4379328087 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.1041" @default.
• W4379328087 hasPublicationYear "2023" @default.
• W4379328087 type Work @default.
• W4379328087 citedByCount "1" @default.
• W4379328087 countsByYear W43793280872023 @default.
• W4379328087 crossrefType "journal-article" @default.
• W4379328087 hasAuthorship W4379328087A5013557141 @default.
• W4379328087 hasAuthorship W4379328087A5021649332 @default.
• W4379328087 hasAuthorship W4379328087A5043744905 @default.
• W4379328087 hasAuthorship W4379328087A5049174232 @default.
• W4379328087 hasAuthorship W4379328087A5064032265 @default.
• W4379328087 hasAuthorship W4379328087A5066943426 @default.
• W4379328087 hasAuthorship W4379328087A5089865552 @default.
• W4379328087 hasAuthorship W4379328087A5090622915 @default.
• W4379328087 hasConcept C112705442 @default.
• W4379328087 hasConcept C121608353 @default.
• W4379328087 hasConcept C126322002 @default.
• W4379328087 hasConcept C143998085 @default.
• W4379328087 hasConcept C197934379 @default.
• W4379328087 hasConcept C2775930923 @default.
• W4379328087 hasConcept C2777511904 @default.
• W4379328087 hasConcept C2778087150 @default.
• W4379328087 hasConcept C2778375690 @default.
• W4379328087 hasConcept C2779786085 @default.
• W4379328087 hasConcept C2781164504 @default.
• W4379328087 hasConcept C31760486 @default.
• W4379328087 hasConcept C530470458 @default.
• W4379328087 hasConcept C535046627 @default.
• W4379328087 hasConcept C71924100 @default.
• W4379328087 hasConcept C98274493 @default.
• W4379328087 hasConceptScore W4379328087C112705442 @default.
• W4379328087 hasConceptScore W4379328087C121608353 @default.
• W4379328087 hasConceptScore W4379328087C126322002 @default.
• W4379328087 hasConceptScore W4379328087C143998085 @default.
• W4379328087 hasConceptScore W4379328087C197934379 @default.
• W4379328087 hasConceptScore W4379328087C2775930923 @default.
• W4379328087 hasConceptScore W4379328087C2777511904 @default.
• W4379328087 hasConceptScore W4379328087C2778087150 @default.
• W4379328087 hasConceptScore W4379328087C2778375690 @default.
• W4379328087 hasConceptScore W4379328087C2779786085 @default.
• W4379328087 hasConceptScore W4379328087C2781164504 @default.
• W4379328087 hasConceptScore W4379328087C31760486 @default.
• W4379328087 hasConceptScore W4379328087C530470458 @default.
• W4379328087 hasConceptScore W4379328087C535046627 @default.
• W4379328087 hasConceptScore W4379328087C71924100 @default.
• W4379328087 hasConceptScore W4379328087C98274493 @default.
• W4379328087 hasIssue "16_suppl" @default.
• W4379328087 hasLocation W43793280871 @default.
• W4379328087 hasOpenAccess W4379328087 @default.
• W4379328087 hasPrimaryLocation W43793280871 @default.
• W4379328087 hasRelatedWork W2085871826 @default.
• W4379328087 hasRelatedWork W2112335800 @default.
• W4379328087 hasRelatedWork W2163622510 @default.
• W4379328087 hasRelatedWork W2905960639 @default.
• W4379328087 hasRelatedWork W2944154894 @default.
• W4379328087 hasRelatedWork W3088751691 @default.
• W4379328087 hasRelatedWork W3123611170 @default.
• W4379328087 hasRelatedWork W3174405896 @default.
• W4379328087 hasRelatedWork W4206299960 @default.
• W4379328087 hasRelatedWork W4281733293 @default.
• W4379328087 hasVolume "41" @default.
• W4379328087 isParatext "false" @default.
• W4379328087 isRetracted "false" @default.
• W4379328087 workType "article" @default.